Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

BioTie signs with Lundbeck and Roche

December 4, 2006 | A version of this story appeared in Volume 84, Issue 49

The Finnish biotech company BioTie Therapies has granted the Danish firm H. Lundbeck rights in much of the world to nalmefene, a substance-abuse treatment under evaluation by British medical authorities. BioTie will get an execution fee of $20 million and is eligible for up to $115 million in milestone payments. Separately, Roche will pay BioTie $6.5 million for an option to license BioTie's antibody program targeting vascular adhesion protein-1 in inflammatory diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.